EMERYVILLE, Calif.,
March 25, 2021 /PRNewswire/
-- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic
biotechnology company active in the Clean Health and Beauty markets
through its consumer brands and a top supplier of sustainable and
natural ingredients, announced today the achievement of another
breakthrough with its production of Cannabigerol (CBG) from
fermentation for consumer skincare treatment formulations.
In the first quarter Amyris achieved a new level of quality,
cost and volume targets with its production run of CBG from
fermentation. Amyris believes that this production run is the
largest industrial-scale fermentation-based CBG by any producer
to-date. The production was completed utilizing 225,000 fermenters
at the facility of Amyris's Spain-based manufacturing partner.
Amyris's Lab-to-Market synthetic biology platform continues to
demonstrate its capability to engineer yeast to create and produce
differentiated high value products. During 2020, Amyris developed
its CBG molecule from initial target to production at scale in less
than nine months and realized first revenue from CBG in the fourth
quarter of 2020. This year's production volume is spoken for with
an expected one million retail units to be sold over the course of
the next twelve months.
Amyris's CBG molecule is the latest addition to its portfolio of
natural, sustainably sourced ingredients powering consumer products
and contains no trace of THC (or tetrahydrocannabinol). Amyris has
completed clinical studies comparing CBG to CBD (cannabidiol)
validating the significant performance advantages of CBG over CBD
for various skin care applications and treatments. Amyris plans to
initially target its CBG towards its consumer brands formulations
and a few selective consumer channel partners. Amyris owned
consumer brands are among the fastest growing in the clean beauty
space with high performing products that are good for our
planet.
"We are very pleased with the breakthrough execution by our
manufacturing team," commented John
Melo, President and Chief Executive Officer of Amyris. "We
continue to demonstrate market leadership in natural, sustainably
sourced fermentation-based ingredients. Our proven development and
production capabilities, our continued consumer sales performance
and the anticipated completion of the previously communicated
strategic transactions by the end of this month are expected to set
us up for record performance this year."
About Amyris
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 3,000 products from the world's top brands,
reaching more than 200 million consumers. Amyris is proud to own
three consumer brands - all built around its No Compromise® promise
of clean ingredients: Biossance® clean beauty skincare,
Pipette® clean baby skincare and Purecane™, a zero-calorie
sweetener naturally derived from sugarcane. For more information,
please visit www.amyris.com.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding Amyris's plans to produce and
commercialize its CBG molecule in consumer brand formulations for
skincare applications and treatments through distribution via
select channel partners, and the timing thereof, and Amyris's
expectation of completing by month-end previously communicated
strategic transactions, which are expected contribute to Amyris's
success during the year. These statements are based on management's
current expectations, and actual results and future events may
differ materially due to risks and uncertainties, including risks
related to delays or failures in completing strategic transactions,
Amyris's liquidity and ability to fund operating and capital
expenses, risks related to potential delays or failures in
development, regulatory approval, production and commercialization
of products, risks related to Amyris's reliance on third parties,
and other risks detailed from time to time in filings Amyris makes
with the Securities and Exchange Commission, including Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Amyris disclaims any obligation to update
information contained in these forward-looking statements, whether
as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and
Purecane are trademarks or registered trademarks of Amyris, Inc. in
the U.S. and/or other countries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amyris-delivers-record-production-of-cbg-for-consumer-skincare-formulations-301255885.html
SOURCE Amyris, Inc.